{"id":3808,"date":"2026-11-05T09:56:21","date_gmt":"2026-11-05T14:56:21","guid":{"rendered":"https:\/\/zenithpv.ca\/?p=3808"},"modified":"2026-11-05T14:43:37","modified_gmt":"2026-11-05T19:43:37","slug":"how-does-notification-of-foreign-actions-nfas-in-canada-compare-to-regulatory-intelligence","status":"publish","type":"post","link":"https:\/\/zenithpv.ca\/fr\/2026\/11\/05\/how-does-notification-of-foreign-actions-nfas-in-canada-compare-to-regulatory-intelligence\/","title":{"rendered":"How does Notification of Foreign Actions (NFAs) in Canada Compare to Regulatory Intelligence?"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Patient safety measures continue to evolve globally, particularly with the increased number of emerging specialty medicines. Traditional initiatives focused on reactive response to recorded trends can no longer support the purpose of Pharmacovigilance. The PV landscape is shifting to predictive PV and proactive measures. What drives patient safety today in the era of increased use of technology and artificial intelligence requires foresight and thinking beyond retrospective benefit-risk assessment.<\/span><\/p>\n

What additional measures did Health Canada introduce to protect Canadian patients beyond routine GVPs?\u00a0<\/h4>\n

<\/span><\/p>\n

With the amendment of the Canadian Food and Drugs Act, <\/em><\/strong>Health Canada implemented a series of regulatory measures to ensure proactive patient safety monitoring and early product risk identification. Starting with enacting Vanessa\u2019s Law <\/em><\/strong>directly contributing to added product safety-risk visibility mandating Canadian hospitals to report serious ADRs & MDIs related to Pharmaceuticals and Medical devices, all the way to the implementation of Notification of Foreign Actions<\/strong> regulation requiring Canadian MAHs to proactively identify and assess foreign risks that could impact Canadian patients.<\/span><\/p>\n

<\/span><\/p>\n

Basic processes may support regulatory and GVP compliance in the short-term. Understating the purpose behind each regulation and building a cohesive structure, with a clear decision-tree and a well-tested communication plan is what makes those processes sustainable to serve the purpose. \u00a0<\/span><\/p>\n

<\/span><\/p>\n

International MAHs may have limited working knowledge of the intricacies of Health Canada GVP regulations. Often times Regulatory Intelligence describes the process of staying up-to-date with the evolving regulatory guidance of the different health authorities. Safety signal detection and emerging safety issue monitoring might be limited to routine ICSRs and safety relevant information.<\/span><\/p>\n

<\/span><\/p>\n

Here are the key requirements that make NFA regulation unique in supporting patient safety:<\/strong><\/span><\/h5>\n

<\/span><\/p>\n